Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy

By Iacopo Olivotto, F. Cecchi, S. Casey, A. Dolara, J. Traverse, B. Maron. Circulation, 2001

824 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation (2017, background): “In patients with HCM, development of AF is associated with marked exacerbation of symptoms, increased risk of stroke, and excess HCMrelated mortality.(1043) Due to the association of AF with HCM-related morbidity and mortality, there is general agreement that vigorous maintenance of sinus rhythm sho”
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014, neutral): “Anticoagulation is indicated in patients with HCM with AF independent of the CHA2DS2-VASc score (169, 170).”
Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. (2014, background): “AF may not be well tolerated when associated with LV outflow tract obstruction, and not uncommonly occurs in patients with systolic dysfunction and advanced HF (end-stage) (18,90).”
EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. (2016, neutral): “fibrillation is relatively common in hypertrophic cardiomyopathy (prevalence 20%).(156) In arrhythmogenic right ventricular cardiomyopathy, an even higher proportion (up to 40%) of patients may manifest AF.”